News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
702,200 Results
Type
Article (41477)
Company Profile (252)
Press Release (660471)
Section
Business (206298)
Career Advice (2092)
Deals (35668)
Drug Delivery (108)
Drug Development (82050)
Employer Resources (170)
FDA (16408)
Job Trends (15109)
News (349280)
Policy (33472)
Tag
Academia (2613)
Alliances (50069)
Alzheimer's disease (1347)
Approvals (16383)
Artificial intelligence (204)
Bankruptcy (363)
Best Places to Work (11771)
Biotechnology (178)
Breast cancer (229)
Cancer (1751)
Cardiovascular disease (135)
Career advice (1743)
CAR-T (124)
Cell therapy (361)
Clinical research (66024)
Collaboration (679)
Compensation (370)
COVID-19 (2627)
C-suite (160)
Data (1641)
Diabetes (227)
Diagnostics (6340)
Earnings (86067)
Employer resources (147)
Events (112200)
Executive appointments (567)
FDA (17324)
Funding (611)
Gene therapy (258)
GLP-1 (732)
Government (4699)
Healthcare (19115)
Infectious disease (2745)
Inflammatory bowel disease (124)
Interviews (334)
IPO (16543)
Job creations (3780)
Job search strategy (1479)
Layoffs (458)
Legal (8075)
Lung cancer (261)
Manufacturing (244)
Medical device (13457)
Medtech (13462)
Mergers & acquisitions (19495)
Metabolic disorders (614)
Neuroscience (1768)
NextGen: Class of 2025 (6636)
Non-profit (4585)
Northern California (2098)
Obesity (348)
Opinion (212)
Patents (164)
People (57434)
Phase I (20520)
Phase II (29045)
Phase III (21727)
Pipeline (723)
Postmarket research (2616)
Preclinical (8686)
Radiopharmaceuticals (243)
Rare diseases (334)
Real estate (5969)
Regulatory (22458)
Research institute (2362)
Resumes & cover letters (359)
Southern California (1801)
Startups (3620)
United States (18567)
Vaccines (642)
Weight loss (259)
Date
Last 7 days (603)
Last 30 days (2496)
Last 365 days (34770)
2025 (4486)
2024 (35612)
2023 (40444)
2022 (51622)
2021 (56260)
2020 (54757)
2019 (47414)
2018 (35723)
2017 (32582)
2016 (32089)
2015 (38127)
2014 (31806)
2013 (26776)
2012 (28973)
2011 (29659)
2010 (27723)
Location
Africa (752)
Arizona (216)
Asia (38151)
Australia (6306)
California (4786)
Canada (1734)
China (398)
Colorado (217)
Connecticut (232)
Europe (82234)
Florida (693)
Georgia (165)
Illinois (463)
Indiana (265)
Maryland (746)
Massachusetts (3627)
Michigan (199)
Minnesota (338)
New Jersey (1355)
New York (1365)
North Carolina (841)
Northern California (2098)
Ohio (173)
Pennsylvania (1103)
South America (1124)
Southern California (1801)
Texas (703)
Utah (143)
Washington State (470)
702,200 Results for "eli lilly canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
Lilly’s I&I Push Gains Momentum With Omvoh Expansion
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according to analysts from BMO Capital Markets.
January 16, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Lilly Signs Back-to-Back Deals in MASH, Cancer
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals and another for cancer therapies with Australia’s AdvanCell.
February 11, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Lilly Makes $780M+ IPF Play with Mediar Partnership
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early studies have found to be safe and capable of engaging its target.
January 10, 2025
·
2 min read
·
Tristan Manalac
Earnings
Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
January 14, 2025
·
2 min read
·
Dan Samorodnitsky
Government
Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner
A week after dining with Trump and his team at Mar-a-Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration on key issues affecting the pharma industry.
December 12, 2024
·
2 min read
·
Tristan Manalac
GLP-1
Lilly Asks to Join GLP-1 Compounding Lawsuit
Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its interests.
January 3, 2025
·
2 min read
·
Nick Paul Taylor
Editorial
Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers
Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler stocking decisions.
November 1, 2024
·
3 min read
·
Greg Slabodkin
Venture capitalists
Lilly Partners With a16z on $500M VC Fund for Early-Stage Biotechs
The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) with Eli Lilly’s expertise in R&D—plus half a billion in capital from the Big Pharma.
January 10, 2025
·
1 min read
·
Annalee Armstrong
Opinion
Why Is Novo Outperforming Lilly Despite Having Inferior GLP-1 Products?
Novo Nordisk’s GLP-1s outsell Eli Lilly’s thanks to its superior marketing. Here’s how.
January 3, 2025
·
6 min read
·
Gary Stibel
Earnings
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company has taken the GLP-1 supply chain too far.
February 6, 2025
·
3 min read
·
Annalee Armstrong
1 of 70,220
Next
